Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Riliprubart unveils compelling efficacy in CIDP treatment, fostering improvement among Standard-of-Care (SOC)-Treated participants and igniting a resurgence in SOC-Refractory individuals, accompanied by notable enhancements in disability measures and a reduction in plasma neurofilament light chain.
In the labyrinth of CIDP, where demyelination and inflammation entwine to ensnare the afflicted, compl...
